United Therapeutics Co. (NASDAQ:UTHR) Director Sells $1,138,200.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at approximately $497,962.50. The trade was a 69.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $278.89 on Friday. The firm has a market capitalization of $12.53 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The business’s fifty day moving average price is $324.67 and its 200 day moving average price is $351.68. United Therapeutics Co. has a 12 month low of $230.39 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the company earned $4.36 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on UTHR. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $388.25.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. raised its stake in United Therapeutics by 84.7% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 4,297 shares of the biotechnology company’s stock worth $1,325,000 after acquiring an additional 1,970 shares in the last quarter. Unigestion Holding SA purchased a new position in United Therapeutics during the 1st quarter worth approximately $2,672,000. GAMMA Investing LLC increased its position in United Therapeutics by 29,415.2% during the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock worth $68,422,000 after buying an additional 221,202 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in United Therapeutics by 15.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company’s stock valued at $1,991,000 after buying an additional 769 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC boosted its holdings in shares of United Therapeutics by 1.5% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 5,598 shares of the biotechnology company’s stock valued at $1,975,000 after acquiring an additional 84 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.